PARP INHIBITORS

PARP inhibitors are a class of precision medicines used to treat cancers with specific mutations.

This is a treatment option for advanced prostate cancer patients who are no longer benefiting from hormone therapy. This is useful in patients with specific genetic mutations causing prostate cancer. These drugs target mutations in genes that repair damaged DNA. Targeted therapies include:

Olaparib

Olaparib can be used for patients with a BRCA mutation before or after docetaxel in mCRPC cases. Olaparib can be used for patients whose metastatic cancer has grown or spread after second hormone therapy (abiraterone or enzalutamide) and who have a mutation in a BRCA gene or other gene that repairs DNA in first-line setting.

Rucaparib 

Rucaparib can be used for patients with a BRCA mutation whose cancer has already been treated with both second hormone therapy and chemotherapy (taxane).

Niraparib and Abiraterone 

Niraparib and abiraterone plus prednisone is a new targeted therapy for patients with a BRCA mutation who have not been treated with docetaxel or second hormone therapy and no previous treatment in the metastatic CRPC.

Talazoparib 

Talazoparib, taken with enzalutamide, is another new targeted therapy for patients with a mutation in a BRCA or other DNA-repair gene and MCRPC who have no prior treatment in CRPC setting.